D-glycero-D-gulo-3,7-anhydro-1,2-dideoxy-octitol | 59091-56-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-glycero-D-gulo-3,7-anhydro-1,2-dideoxy-octitol
• 英文别名: (2S,3R,4R,5S,6R)-2-ethyl-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 59091-56-4
• 化学式: C₈H₁₆O₅
• 分子量: 192.212
• InChiKey: ATSGDPDUYBEUBX-BZCSJUTBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  90.2
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  D-glycero-D-gulo-3,7-anhydro-1,2-dideoxy-octitol 在 sodium periodate 作用下， 生成 (S)-2-((R)-1-formyl-2-hydroxy-ethoxy)-butyraldehyde
  参考文献：
  名称：

  Synthesis of?-D-galactopyranosylepoxyethane diastere omers

  摘要：

  DOI：

  10.1007/bf00925651

文献信息

• Novel compounds
  申请人：Nomura Sumihiro

  公开号：US20070060545A1

  公开（公告）日：2007-03-15

  A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH 2 — group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

  该化合物的化学式为：其中环A和环B分别为（1）环A为可选取代的不饱和单环杂环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，（2）环A为可选取代的苯环，环B为可选取代的不饱和单环杂环、可选取代的不饱和融合杂双环或可选取代的苯环，或（3）环A为可选取代的不饱和融合杂双环，其中—NR—基团和—CH2—基团均位于不饱和融合杂双环的同一环上，环B为可选取代的单环不饱和杂环、可选取代的不饱和融合杂双环或可选取代的苯环；R为氢原子、低碳基、低烷酰基或低烷氧羰基基团，或其药学上可接受的盐或前药。
• RAPAMYCIN ANALOGS AND USES THEREOF
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US20210186935A1

  公开（公告）日：2021-06-24

  The present invention provides compounds, compositions thereof, and methods of using the same.
• US7521430B2
  申请人：——

  公开号：US7521430B2

  公开（公告）日：2009-04-21
• US9902986B2
  申请人：——

  公开号：US9902986B2

  公开（公告）日：2018-02-27
• [EN] NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] NOUVEAUX INHIBITEURS DE SGLT2 CONSISTANT EN C-ARYL GLUCOSIDES ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：GREEN CROSS CORP

  公开号：WO2010147430A2

  公开（公告）日：2010-12-23

  A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.